Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP^® (Oxford Genome Anatomy Project) platform. OGAP^® is one of the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities.

OBT’s strategy is to use its unique and integrated OGAP^® discovery platform in alliances with the world’s leading antibody companies to develop OBT targets into novel antibody therapeutics and diagnostics. This approach is expected to deliver innovative and cost-effective medicines to fulfill unmet patient needs in the field of cancer. In parallel, OBT provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies.

Formed in 2004, OBT is privately held and is based near Oxford, UK.